Global Dyslipidemia market is anticipated to grow at a CAGR of around 10% during 2020-25

According to MarkNtel Advisors’ research report titled “Global Dyslipidemia Market Analysis, 2020”, the Global Dyslipidemia market is anticipated to grow at a CAGR of around 10% during 2020-25 due to the growing risk of cardiovascular diseases (CVD) and rising cholesterol levels among the population. Besides this, increasing prevalence of dyslipidemia in developed countries, high rate of heart strokes and ischemic heart diseases in emerging economies such as India and China, and a boost in the discovery of new drugs for the treatment of lipid disorders is projected to infuse a significant impact toward the growth of Dyslipidemia market in the forecast period.

 

Based on type, drug segment acquired the majority market share in the Global Dyslipidemia market in 2019. Statins dominated the drug segment market owing to the escalating usage of statins drugs to reduce the risk of CVD and to control bad cholesterol levels in the body. The demand for Omega-3 fatty acid drugs is also increasing due to accelerating patient inclination toward the use omega-3 fatty acid derivatives for treating hypertriglyceridemia.

 

North America captured the largest market share in Global Dyslipidemia market in 2019 owing to the growing occurrence of diseases in the country, leading to hypercholesterolemia and cholesterol disorders, resulting in advanced levels of health awareness among the citizens. Canada and United States are among the major contributors in the North America Dyslipidemia market on an account of burgeoning number of obese and diabetic patients, initiation of favorable government policies, and growth in pharmaceutical manufacturing, which are anticipated to accelerate the growth of the Dyslipidemia market in the region in the forthcoming period as stated in the MarkNtel Advisors’ research report “Global Dyslipidemia Market Analysis, 2020”. 

 

According to MarkNtel Advisors, the key players with a considerable market share in the Global Dyslipidemia market are Merck, Pfizer, Sanofi, Bristol-Myers Squibb, Abionyx (Cerenis), Cipla, Daewoong Pharmaceutical, Daiichi Sankyo, Novartis, Amgen etc.